ABBV AbbVie Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1551152 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY-1.2%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR-29.1%
Margins
Gross margin70.2%
Operating margin24.6%
Net margin6.9%
FCF margin29.1%
EBITDA margin25.9%
Returns
ROE15,367.3%
ROA3.1%
ROIC (approx.)17.4%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets102.4%
Debt / equity—
Current ratio0.67x
Interest coverage5.21x
Cash quality & payout
Operating cash flow / net income4.50x
Accruals ratio-11.0%
Payout ratio275.8%
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17.40B | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B |
| Cost of revenue | $4.29B | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B |
| Gross profit | $13.12B | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B | $9.34B | $10.71B |
| R&D expense | $2.57B | $2.34B | $2.47B | $2.58B | $2.32B | $2.13B | $2.07B | $6.77B |
| SG&A expense | $4.09B | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B |
| Operating income | $6.27B | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | -$1.49B |
| Interest expense | $802.00M | $746.00M | $717.00M | $714.00M | $739.00M | $740.00M | $700.00M | $702.00M |
| Pretax income | $4.83B | $4.28B | $1.04B | $2.67B | $714.00M | $1.55B | $1.66B | -$2.27B |
| Income tax | $609.00M | $662.00M | $342.00M | $853.00M | $526.00M | $613.00M | $372.00M | -$2.25B |
| Net income | $4.22B | $3.61B | $695.00M | $1.82B | $186.00M | $938.00M | $1.29B | -$22.00M |
| EBITDA | $6.46B | $6.63B | $4.18B | $4.75B | $2.10B | $5.08B | $3.91B | -$1.28B |
| EPS (basic) | 2.38 | 2.04 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 |
| EPS (diluted) | 2.37 | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 |
| Dividends declared per share | 1.73 | 1.73 | 1.73 | 1.73 | 1.64 | 1.64 | 1.64 | 1.64 |
| Weighted avg. shares (diluted) | 1.77B | 1.77B | 1.77B | — | 1.77B | 1.77B | 1.77B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.77B | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B |
| Short-term investments | — | — | — | $28.00M | $42.00M | $0 | $1.00M | $31.00M |
| Receivables | $13.51B | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B |
| Inventory | $5.30B | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B |
| Current assets | $37.48B | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B |
| PP&E, net | $5.94B | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B |
| Goodwill | $37.80B | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B |
| Intangibles | $56.65B | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B |
| Total assets | $147.68B | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B |
| Current liabilities | $43.10B | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B |
| Short-term debt | $0 | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 |
| Long-term debt | $72.23B | $62.48B | $64.53B | $58.94B | $62.97B | $62.96B | $64.53B | $60.34B |
| Total debt | $72.23B | $62.48B | $64.53B | $61.44B | $66.76B | $68.52B | $66.12B | $60.34B |
| Total liabilities | $152.22B | $141.00B | $143.07B | $137.19B | $136.50B | $137.32B | $134.70B | $131.80B |
| Shareholders' equity | -$4.58B | -$5.93B | -$6.66B | -$3.27B | -$2.64B | -$183.00M | $1.42B | $3.33B |
| Net debt | $61.46B | $55.91B | $55.14B | $56.21B | $61.13B | $62.05B | $60.95B | $54.82B |
| Cash flow statement | ||||||||
| Operating cash flow | $7.61B | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B |
| Capital expenditure | $301.00M | $322.00M | $265.00M | $329.00M | $381.00M | $269.00M | $235.00M | $291.00M |
| Free cash flow | $7.30B | $3.11B | $3.56B | $4.89B | $6.64B | $4.88B | $1.40B | $6.76B |
| Investing cash flow | -$10.21B | -$1.20B | -$574.00M | -$1.46B | -$3.26B | -$1.18B | -$735.00M | -$1.87B |
| Financing cash flow | $6.82B | -$5.05B | $919.00M | -$4.17B | -$4.59B | -$2.71B | -$1.26B | -$6.86B |
| Depreciation & amortization | $192.00M | $194.00M | $188.00M | $203.00M | $192.00M | $186.00M | $181.00M | $206.00M |
| Stock-based compensation | $160.00M | $166.00M | $444.00M | $157.00M | $209.00M | $179.00M | $410.00M | $164.00M |
| Dividends paid | $3.07B | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B |
| Share buybacks | $5.00M | $9.00M | $1.49B | $3.00M | $4.00M | $12.00M | $961.00M | $358.00M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.